Recent investigations have converged on the overlap of glucagon-like peptide-1|GIP|glucagon receptor activator therapies and dopaminergic Pramipexole signaling. While GIP stimulators are commonly employed for addressing type 2 diabetes mellitus, their unexpected effects on motivation circuits, specifically mediated by dopamine pathways, are gaining